Cellogen Therapeutics
A Delhi start-up developing bispecific CD19 and CD20 CAR-T cells and gene therapies for thalassaemia, aiming to cut treatment costs by up to 90%; still before its first trial.
Overview
Cellogen Therapeutics is a New Delhi company developing bispecific, third- and fourth-generation CAR-T cells that target CD19 and CD20 at the same time to reduce antigen-loss relapse, plus genetic therapies for beta-thalassaemia and sickle cell disease. As of its public statements it reports promising laboratory results and plans to begin clinical trials; it has no approved products. It is one of a growing group of Indian cell therapy start-ups following ImmunoACT and Immuneel, and its stated aim is to reduce treatment costs by up to 90% with indigenous products.
Pages like this
not linked directly; found by shared links- CompanyLyell Immunopharma
Shares CD20, CD19, Diffuse large B-cell lymphoma, CAR-T cell therapy.
- IdeaNon-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route
Shares CD19, Manufacturing cost and time for living and radioactive medicines, Diffuse large B-cell lymphoma, CAR-T cell therapy.
- CompanyImugene
Shares CD19, Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma, CAR-T cell therapy.
- IdeaPlan the second CAR-T target before the first one is lost
Shares CD20, CD19, Manufacturing cost and time for living and radioactive medicines, Acute lymphoblastic leukaemia.
- CompanyLEAH Labs
Shares CD20, Diffuse large B-cell lymphoma, CAR-T cell therapy.
- PersonJae H. Park
Shares CD19, Acute lymphoblastic leukaemia, CAR-T cell therapy.
- IdeaCollect and freeze T cells at diagnosis for high-risk patients, before chemotherapy
Shares Manufacturing cost and time for living and radioactive medicines, Diffuse large B-cell lymphoma, CAR-T cell therapy.
- IdeaHospital-made CAR-T under one shared regulatory master file
Shares CD19, Manufacturing cost and time for living and radioactive medicines, Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma.